This memo was written from the 2006 deck and the sources available then. Nothing that happened later was used.
Verdict
Confidence · Highnothing here reopens it
Technology unverified, math broken, customers unnamed.
Six deals across five unnamed companies in validation phase cannot be verified, the $50M per-trial revenue figure is arithmetically inconsistent with the deck's own $7,500 per-patient fee, and the FDA regulatory pathway is entirely absent from a deck pitching a diagnostic device for use in regulated clinical trials.
The technology may be real, but this deck provides no evidence that it is.
Why this stage
The one blocker
Core technology claims entirely unverified.
The Phase IV monitoring market is large and underserved, but the deck's $39B TAM is overstated by 2-3x on its own arithmetic (derived), and the realistic monitoring-services slice is not established.
The $30M raise funds manufacturing scale-up and sales force expansion with no disclosed allocation, no runway calculation, and no milestone map, making it impossible to assess whether the capital reaches the next defensible milestone.
The senior operating team carries genuine domain credentials, Howard Bailey's CFO track record, Diane Parks's Genentech relationships, Ian Gibbons's immunoassay development depth, but the company has been operating since 2003 and has not disclosed a single shipped product, cleared regulatory filing, or signed contract.
The claimed moat, on-chip chemiluminescence, integrated informatics, and assay development speed, is entirely contingent on the technology performing as claimed, and no independent validation exists to confirm it does.
What moves this grade
A 7 or 8 requires demonstrated switching costs from a signed, multi-year pharma sponsor contract.
Slide 14 states average Theranos revenue per trial is $50M, but this figure is not derived from the stated $7,500 per-patient fee and patient count ranges (2,000-10,000 patients per trial); the math does not reconcile.
Slide 2 states immediate goal is to become the standard for improving efficacy and risk/benefit and safety profile of every therapy, but deck does not address regulatory approval pathway, clinical validation requirements, or FDA clearance status for the diagnostic platform.
Slide 3 projects $120M-$300M revenue in next 1.5 years from 6 current deals plus 15 pipeline deals, but slide 3 also states existing deals alone project $120M-$1.5Bn in revenue; the two ranges overlap but are not reconciled.
+ 4 more in the full memo
Do next
Pass pending independent analytical validation and FDA filing.
Independent peer-reviewed analytical validation of the ABCS platform, a disclosed FDA clearance filing with a timeline, and at least one named pharma sponsor with a signed contract would reopen this as an Invest.
The full memo
The complete read, with the market and diligence, is built for desktop. Open Verdict on a computer for the full analysis.
Verdict
PASS
Confidence · High · nothing here reopens it
Technology unverified, math broken, customers unnamed.
Six deals across five unnamed companies in validation phase † cannot be verified, the $50M per-trial revenue figure is arithmetically inconsistent with the deck's own $7,500 per-patient fee †, and the FDA regulatory pathway is entirely absent from a deck pitching a diagnostic device for use in regulated clinical trials †.
The technology may be real, but this deck provides no evidence that it is.
Slide 14 states average Theranos revenue per trial is $50M, but this figure is not derived from the stated $7,500 per-patient fee and patient count ranges (2,000-10,000 patients per trial); the math does not reconcile.
At $7,500 per patient per four months, a 2,000-patient trial would generate $15M per four-month cycle, not $50M per trial. Clarify whether $50M is annual, multi-year, or per-cycle revenue, and reconcile with patient count and fee structure.
Slide 2 states immediate goal is to become the standard for improving efficacy and risk/benefit and safety profile of every therapy, but deck does not address regulatory approval pathway, clinical validation requirements, or FDA clearance status for the diagnostic platform.
Clarify FDA regulatory pathway (510(k), PMA, CLIA), clinical validation status, and timeline to regulatory clearance for Phase IV monitoring use.
Slide 3 projects $120M-$300M revenue in next 1.5 years from 6 current deals plus 15 pipeline deals, but slide 3 also states existing deals alone project $120M-$1.5Bn in revenue; the two ranges overlap but are not reconciled.
Clarify whether the $120M-$300M is incremental to the $120M-$1.5Bn from existing deals or if the ranges describe the same revenue pool under different scenarios.
Deck claims 70% gross margins (slide 16) but does not disclose cost of goods sold, manufacturing costs, or cartridge/reader production economics to substantiate the margin claim.
Provide breakdown of costs (cartridge manufacturing, reader production, informatics infrastructure, support) to validate 70% gross margin assumption.
Deck states 6 deals across 5 companies in validation phase (slide 3) but does not disclose which companies, deal status, or revenue recognition timeline.
Name the 5 companies and provide deal status (signed, in negotiation, LOI), expected revenue recognition dates, and patient enrollment timelines.
Slide 16 claims cost to pharmaceutical companies is 20-30% less than current costs of equivalent testing through clinicians' office, but does not disclose what current testing costs are or how the comparison was calculated.
Provide baseline cost data for current testing methods (e.g., central lab testing, clinician office testing) and show calculation of 20-30% savings claim.
Slide 3 projects 15 additional deals with 10 companies and 1 government agency in pipeline, but provides no detail on deal stage, probability of close, or revenue timing.
Provide pipeline deal status (LOI, negotiation, early stage), expected close dates, and revenue recognition timeline.
The Phase IV monitoring market is large and underserved, but the deck's $39B TAM is overstated by 2-3x on its own arithmetic (derived), and the realistic monitoring-services slice is not established.
The $30M raise † funds manufacturing scale-up and sales force expansion with no disclosed allocation, no runway calculation, and no milestone map, making it impossible to assess whether the capital reaches the next defensible milestone.
The senior operating team carries genuine domain credentials, Howard Bailey's CFO track record, Diane Parks's Genentech relationships, Ian Gibbons's immunoassay development depth †, but the company has been operating since 2003 and has not disclosed a single shipped product, cleared regulatory filing, or signed contract.
The claimed moat, on-chip chemiluminescence, integrated informatics, and assay development speed †, is entirely contingent on the technology performing as claimed, and no independent validation exists to confirm it does.
What moves this grade
A 7 or 8 requires demonstrated switching costs from a signed, multi-year pharma sponsor contract.
Each axis is scored from 1 to 10 against a fixed rubric, and the letter is shorthand for that number. A 5 or 6 reads as B, which means the company meets the bar for its category on that axis without clearing it. No band is a default and no band is a target: every company is read on its own evidence, and thin evidence is not a reason to sit in the middle, it is something the reasoning has to name. The outer bands have to be earned: a strong grade needs named, defensible evidence, and a failing grade needs a concrete flaw that capital alone cannot fix. Grades judge the company on its own merits. Whether the company fits a particular investor is judged separately, in the verdict. The reasoning under each grade is anchored in what the deck disclosed, plus outside research where cited.
Biggest risk
The core technology claims are entirely unverified: no peer-reviewed validation, no named clinical study, and no independent lab confirmation that the platform achieves the stated accuracy from 5-10µL blood samples †.
Weighed against it, and ranked lower
Best reason
If the technology performs as claimed, the integrated cartridge-reader-informatics workflow creates genuine switching costs for pharma sponsors who embed it in trial protocols, and the 70% margin profile is consistent with the best public analog in the category [2].
Would change mind
Independent peer-reviewed analytical validation of the ABCS platform, a disclosed FDA clearance filing with a timeline, and at least one named pharma sponsor with a signed contract would reopen this as an Invest.
Why this verdict
Technology validity is unestablished: the entire investment thesis rests on a scientific claim the deck never supports with independent evidence.
FDA regulatory pathway is absent: every dollar of projected revenue requires clearance the deck never mentions, making the 1.5-year revenue timeline structurally unreachable as disclosed.
Revenue math is internally inconsistent: the $50M per-trial figure used to construct the $39B TAM does not reconcile with the deck's own $7,500 per-patient fee and enrollment ranges (derived).
Investment thesis
Theranos targets a structural gap in pharmaceutical trial monitoring: central lab CROs return results in days, which is too slow for real-time dose adjustment in narrow-therapeutic-index drugs. The ABCS platform, cartridge, reader, and informatics, is designed to close that gap with 30-minute turnaround from a 5-10µL fingerstick sample †.
The thesis fails on one condition
The technology must perform as claimed. Nothing in this deck establishes that it does.
GP summary
The thesis is correct and the problem is real.
Point-of-care diagnostics enabling real-time pharma trial monitoring.
Key strength
Experienced senior team; domain-relevant strategic investors.
Key risk
No independent validation that the platform works.
Signal
Unverified technology, broken revenue math, unnamed customers.
Round size
$30M
Valuation
Not disclosed
Lead status
Not disclosed
Allocation available
Not disclosed
Pro-rata rights
Not disclosed
Board seat
Not disclosed
Use of proceeds
Objective stated as pre-IPO transaction to facilitate rapid scaling of Theranos production and manufacturing infrastructure and add to business development and sales force. Specific allocation percentages not disclosed.
Pass on current evidence, with a clear path back if three things are resolved.
Post-marketing surveillance reform pressure reached a legislative inflection point in 2006. The FDA's post-marketing surveillance system had been under sustained criticism following high-profile drug withdrawals (Vioxx, 2004), and the AMA Journal of Ethics published analysis in June 2006 noting that the FDA's authority over post-approval safety was structurally constrained [1]. Pharmaceutical companies faced growing regulatory and reputational pressure to demonstrate real-world drug safety, creating demand for monitoring infrastructure that did not yet exist at scale.
What’s helping
$3B+ in capital commitments per deck) and the Series A investor base (including Draper Fisher Jurvetson) provide distribution credibility with pharma business development teams †.What’s in the way
$50M average revenue per trial † is inconsistent with $7,500 per patient across 2,000-10,000 patients †, which yields $15M-$75M per four-month cycle. The TAM and per-deal revenue figures cannot both be correct as stated.Timing risk.Too early is the primary risk. Pharma sponsors will not embed an uncleared, unvalidated platform in FDA-required Phase IV studies. If regulatory clearance takes 2-4 years and clinical validation requires peer-reviewed publication, the $120M-$300M revenue in 1.5 years milestone † is structurally unreachable on the disclosed timeline.
Value proposition
Real-time PK/PD monitoring replacing slow central lab workflows.
Business model
$7,500 per-patient information fee, 70% stated gross margin.
Funding
$30M Series B offering; DFJ and domain-adjacent strategic investors.
Not disclosed · Series B, $30M offering (CFP structure)
Product
Theranos ABCS (Ambulatory BioInformatics Communications System) is a point-of-care diagnostic platform consisting of three components: (1) Cartridges containing chemiluminescent immunoassay reagents for simultaneous quantitative…
Theranos ABCS (Ambulatory BioInformatics Communications System) is a point-of-care diagnostic platform consisting of three components: (1) Cartridges containing chemiluminescent immunoassay reagents for simultaneous quantitative measurement of drugs and treatment-related biomarkers from 5-10µL blood samples; (2) Portable readers that perform multiplex assays in under 30 minutes with on-board calibration and control; (3) Informatics service that receives data, performs dose-response calculations via factory-calibrated algorithms, and enables real-time monitoring and dose adjustment. System enables narrow-range therapy through post-prescription monitoring of the total available patient base.
Operating principle: Chemiluminescent/Immunoassay. Dynamic range: low picogram/mL to high microgram/mL. Accuracy comparable to gold standards. Precision: average 5-7% Coefficient of Variation or better. Data reporting: immediate upload from secured server. New assays can be developed and implemented within three months and fully developed at ISO 9000 standards within six months. On-chip chemiluminescence enables greater sensitivity than clinical lab assays.
Platform vs. pointPlatform. The system integrates cartridge, reader, and informatics into a unified workflow capable of monitoring multiple drugs and biomarkers simultaneously across different therapeutic areas. The informatics layer enables real-time dose adjustment and compliance monitoring across the entire patient base for a given therapy.
Founding arc
Elizabeth Holmes left Stanford Chemical and Electrical Engineering to found Theranos in 2003 with the conviction that real-time drug monitoring could improve pharmaceutical efficacy and safety. The company built a platform combining cartridge-based chemiluminescent assays, portable readers, and informatics services to address the gap in post-prescription and trial-phase monitoring where current testing procedures are too slow, expensive, or impossible for some drugs.
Team · 50 people
Elizabeth Holmes
President and CEO
Left Stanford Chemical and Electrical Engineering to found Theranos; also Genencor, Genome Institute Singapore
Profile found
Open profileElizabeth Holmes · President and CEO
Left Stanford Chemical and Electrical Engineering to found Theranos; also Genencor, Genome Institute Singapore
FitFounded company to solve pharmaceutical efficacy and safety monitoring; prior experience in chemical engineering and biotech suggests domain expertise in assay development and biotech operations.
Howard Bailey (CFO) is a former CFO who took QED and Photon Dynamics public, also CFO at Occam, C-Cube, and Controller at Intel. Diane Parks (CCO) is former Senior Vice President of Biotherapeutics and Managed Care at Genentech, also VP Marketing at Aventis. John Howard (Senior VP Products) is former President at Panasonic Semiconductor and President at IBM Microelectronics Division. Dr. Ian Gibbons (Senior Director Assay Development) is former Senior Director at Syva, ACI ABA, Biotrack, AmCell, First Medical. Tim Kemp (Senior Director Informatics Systems) is former lead systems engineer at IBM Embedded Systems. Board includes Donald L. Lucas (Chairman, 46-year venture capital veteran), Peter Thomas (Founder and Managing Director ATA Ventures; General Partner Institutional Venture Partners), Channing Robertson (Stanford Senior Associate Dean of Engineering).
Traction
Market sizing
$120M-$300M in the next 1.5 years from 6 current deals plus 15 pipeline deals, are milestone targets, not a current-state capture figure. At the $7,500 per-patient fee, 6 validation-phase deals at 2,000-10,000 patients each would generate $90M-$450M per four-month cycle if all deals were in full Phase IV monitoring, but the deals are currently in validation phase, not full Phase IV. No SOM can be established from the deck's disclosed data without knowing deal conversion rates and patient enrollment timelines.How each figure was built
Phase IV post-marketing clinical trial monitoring spend addressable by real-time pharmacokinetic/pharmacodynamic diagnostic services
Slide 14: '600-800 ongoing trials per year, average $50M revenue per trial'
Pharmaceutical preclinical research monitoring market across large pharma companies' internal research groups
Slide 15: '$5M annual revenue per research group, 133 groups per pharmaceutical company, 15 companies of this size'
Not established
Revenue Theranos could realistically capture from Phase IV and preclinical monitoring within a 3-5 year horizon given current deal pipeline and competitive position
Phase IV clinical trial market, as stated by the deck. The deck derives this from 600-800 ongoing Phase IV trials per year at an average of $50M revenue per trial. The $50M per-trial figure does not reconcile with the stated $7,500 per-patient fee across 2,000-10,000 patients, which would yield $15M-$75M per trial per four-month cycle, not per trial overall. The deck's arithmetic is internally inconsistent and the TAM figure should be treated as the founder's stated ceiling, not a verified number.
Deck-stated figure. The deck multiplies 600-800 Phase IV trials by an average of $50M revenue per trial to reach $30B-$40B, rounded to $39B. The $50M per-trial figure is not reconciled with the $7,500 per-patient fee and 2,000-10,000 patient enrollment range stated elsewhere in the deck, at $7,500 per patient per four-month cycle, a 2,000-patient trial generates $15M per cycle, not $50M per trial. The TAM is therefore the founder's stated figure and should be validated independently.
SourceDeck slide 14; cross-checked against Duke University / Health Affairs study on post-approval drug safety spending (2006)
Pharmaceutical preclinical market, as stated by the deck. Derived from 15 large pharmaceutical companies, each with 133 research groups, at $5M annual revenue per group. This is the deck's stated SAM for the preclinical segment, which is a distinct and adjacent market to the Phase IV TAM above. The two figures describe different buyer segments and are not additive without further decomposition.
Deck-stated figure: 15 large pharma companies × 133 research groups × $5M per group = $9.975B, rounded to $10B. The $5M per-group figure is an assumption not sourced to a third party. The 133-groups-per-company figure is also unverified. Treat as founder's stated SAM.
SourceDeck slide 15
Not established
The deck does not state a SOM. The deck's milestone revenue projections, $120M-$300M in the next 1.5 years from 6 current deals plus 15 pipeline deals, are milestone targets, not a current-state capture figure. At the $7,500 per-patient fee, 6 validation-phase deals at 2,000-10,000 patients each would generate $90M-$450M per four-month cycle if all deals were in full Phase IV monitoring, but the deals are currently in validation phase, not full Phase IV. No SOM can be established from the deck's disclosed data without knowing deal conversion rates and patient enrollment timelines.
The basis for this figure is not established. The deck provides milestone revenue projections but no current-state capture figure. The $7,500 per-patient fee is disclosed, but patient enrollment timelines, deal conversion rates from validation to Phase IV, and competitive win rates are not disclosed. A bottom-up SOM would require these inputs.
Supporting data points
Caveats
$50M average revenue per trial † but also states a $7,500 per-patient fee with 2,000-10,000 patients per trial †, at those inputs, a 2,000-patient trial generates $15M per four-month cycle, not $50M per trial.$800M in 2003 (mean $56M per company) [3], a figure that is orders of magnitude smaller than the deck's $39B TAM.71% gross margin on product sales in full-year 2005 [4].Market analysis
The Phase IV clinical trial monitoring market is real and underserved.
Competitive analysis
The primary competition is the existing central lab CRO workflow, not a funded startup.
Section sources
Competitive position
Funding · max-of-disclosedNot plottedTheranos (no funding disclosed); Central laboratory CROs (Covance, PPD, Quintiles) (no funding disclosed)
Competitive set
Biosite ships a portfolio of point-of-care immunoassay diagnostic tests, anchored by the Triage BNP Test for heart failure diagnosis, sold primarily to urgent care hospitals [2]. Its business model is cartridge-based, with direct sales to approximately 5,400 US urgent care hospitals and international distribution in France, Germany, Belgium, Luxembourg, the UK, Italy, and the Netherlands [2]. Biosite's platform is FDA-cleared and CLIA-categorized; its products are in production and deployed to customers.
Ships
Funding / scale
Public company (Nasdaq: BSTE); $287.7M total revenues FY2005, 17% year-over-year growth [2].
Strength.FDA-cleared, commercially deployed cartridge-based POC immunoassay platform with 71% gross margin on product sales in FY2005 and a validated clinical evidence base [2].
Gap.Focused on urgent care hospital diagnostics, not pharmaceutical trial monitoring or real-time PK/PD dose adjustment; no informatics layer for trial-sponsor reporting.
Abbott ships the i-STAT point-of-care system, a handheld cartridge-based analyzer providing bedside blood chemistry and cardiac biomarker results in urgent and intensive care settings [2]. Abbott announced plans to add a BNP test to the i-STAT platform as of 2005 [2]. Abbott is a global diagnostics leader with approximately 70,000 customers in more than 100 countries. The source does not state whether the i-STAT BNP test was live or still forthcoming as of mid-2006.
Ships
Funding / scale
Public company (NYSE: ABT); global diagnostics leader with ~70,000 customers in 100+ countries.
Strength.Global scale, established hospital relationships, broad cartridge menu, and FDA clearance across multiple i-STAT assays already in production.
Gap.Designed for urgent care clinical settings, not pharmaceutical trial monitoring; no informatics layer for sponsor-facing PK/PD reporting or dose-adjustment alerts.
Contract research organizations providing centralized laboratory services for clinical trial monitoring. These firms process blood samples collected at trial sites and return results on timelines measured in days, not minutes. They are the incumbent workflow Theranos is positioning against. No single CRO is named in the deck; the category represents the status quo against which Theranos claims a 20-30% cost advantage and a speed advantage †. The source does not state individual CRO revenues for 2006.
Ships
Strength.Established regulatory relationships, validated assay menus, existing contracts with major pharma sponsors, and CLIA-certified laboratory infrastructure already in production.
Gap.Results turnaround measured in days; no real-time dose-adjustment capability; cannot monitor patients outside clinical sites; higher per-test cost than Theranos claims.
Moat assessment
Primary competition. Incumbent centralized laboratory CROs and large diagnostic instrument companies; the primary competition is the existing manual, centralized-lab workflow rather than other funded startups in this specific niche
Durability. The moat is entirely contingent on the technology performing as claimed. The deck does not disclose FDA clearance status, CLIA certification, or peer-reviewed clinical validation data, the three things that would confirm the platform works at the stated sensitivity and precision.
71% gross margins [4] on a validated, cleared platform built over more than a decade. Theranos claims the same margin at pre-revenue stage with no disclosed regulatory status. If the technology is real, the integrated cartridge-reader-informatics workflow creates genuine switching costs for pharma sponsors who embed it in trial protocols. If the technology does not perform at claimed specifications, there is no moat. The absence of any named pharma customer, any disclosed clinical validation study, or any FDA filing is the central diligence question.Assessment · moderate
Aspirational but not structurally impossible. The margin target is consistent with the public analog at scale. The problem is that Biosite's 71% reflects manufacturing at volume; Theranos at pre-revenue scale almost certainly carries higher per-unit costs. The claim is unverifiable without COGS disclosure and should be treated as a ceiling, not a floor.
Biosite Incorporated, the closest public POC immunoassay analog, reported 71% gross margin on $287.7M FY2005 revenue [2]. No published benchmark exists for pre-revenue diagnostic hardware companies at Series B, Biosite is a scaled public company and the comparison is cross-stage.
Assessment
Unverifiable against a published benchmark. The fee is plausible as a value-based price (replacing central lab testing at higher cost), but the deck's own claim that it represents a 20-30% discount to current testing † is unsourced. Diligence Q: obtain central lab testing cost data for equivalent multiplex assays and confirm the savings claim.
Post-approval drug safety spending across the top 20 pharma manufacturers averaged $56M per company in 2003, roughly 0.3% of sales. No published per-patient monitoring fee benchmark exists for POC diagnostics in Phase IV trials. The $7,500 figure cannot be graded against a peer set.
Assessment · weak
Suspicious. At $7,500 per patient per four-month cycle, a 2,000-patient trial generates $15M per cycle (derived), one-third of the stated figure. The $50M average is arithmetically unsupported by the deck's own pricing and enrollment inputs. This is the single most important number to reconcile before any valuation discussion.
No published benchmark exists for per-trial diagnostic monitoring revenue. The figure is internally inconsistent with the deck's own $7,500 per-patient fee and 2,000-10,000 patient enrollment range †.
No comparable scale (non-percentage metric)
Assessment · weak
Suspicious. The TAM is the deck's own calculation, built on a $50M per-trial figure that does not reconcile with the deck's own pricing inputs. The BCC Research POC diagnostics market of $5-10B is a more defensible external anchor for the addressable hardware and services market, and it is 4-8x smaller than the deck's claim.
The POC diagnostics market was sized at $5.05B in 2005, projected to reach $9.65B by 2010 at 13.8% AAGR. The $39B figure is not the POC diagnostics market, it is the deck's estimate of total Phase IV trial spend addressable by Theranos's monitoring fee. No independent third-party sizing of this specific sub-market was found.
Severity distribution
11 risks surfacedRisk analysis
The risks below are ordered by the degree to which they bind on this deck's own evidence.
Section sources
The deck asserts chemiluminescent immunoassay accuracy 'comparable to gold standards' from 5-10µL blood samples †, but provides zero peer-reviewed validation, no named clinical study, and no independent lab confirmation. A diagnostic platform sold to pharma sponsors for patient safety decisions requires published analytical validation data. Its absence is not a gap, it is the central question.
Mitigant.None identified.
The deck never mentions 510(k), PMA, CLIA certification, or any FDA clearance pathway †. A point-of-care diagnostic device used in Phase IV clinical trials requires regulatory clearance before commercial deployment. No clearance status, no timeline, and no regulatory counsel are disclosed.
Mitigant.None identified.
At $7,500 per patient per four-month cycle †, a 2,000-patient trial generates $15M per cycle, not the $50M per-trial figure the deck uses to construct the $39B TAM †. The TAM is therefore overstated by at least 2-3x on the deck's own inputs (derived).
Mitigant.Diligence Q: provide the full per-trial revenue build, patient count, monitoring cycles, and fee per cycle, and reconcile to the $50M figure.
The $120M-$1.5Bn revenue figure † is a projection from deals in 'validation phase', not signed contracts, not recognized revenue. The 5 unnamed companies and 15 unnamed pipeline deals † carry no LOI status, no close dates, and no revenue recognition timeline.
Mitigant.Confirm signed contract documentation and revenue recognition schedule for all 6 current deals before any capital commitment.
The 5 companies in validation phase and 10 pipeline companies plus 1 government agency † are unnamed. No reference checks, no contract verification, and no independent confirmation of deal status are possible without disclosure. This is a complete due diligence block.
Mitigant.None identified.
The deck claims 70% gross margin † but discloses no COGS: no cartridge manufacturing cost, no reader production cost, no informatics infrastructure cost. Biosite, the closest public analog, reported 71% gross margin on $287.7M revenue [2], a mature, scaled business. Theranos at pre-revenue scale almost certainly carries higher per-unit costs.
Mitigant.Diligence Q: full COGS breakdown, cartridge BOM, reader manufacturing, informatics hosting, and field support, at current and projected volumes.
Slide 3 projects $120M-$300M in the next 1.5 years from 6 current plus 15 pipeline deals, while also stating existing deals alone project $120M-$1.5Bn †. The two ranges overlap but are never reconciled, it is unclear whether the $300M ceiling is a subset or a separate scenario.
Mitigant.Require a single, reconciled revenue model with scenario labels before accepting any projection as a valuation anchor.
Elizabeth Holmes † left Stanford without completing her degree and has no prior commercial exit, no prior CEO role, and no disclosed co-founder. The entire scientific and commercial narrative rests on her credibility. The senior team is experienced but none hold equity-level founder stakes that would anchor them through adversity.
Mitigant.None identified.
The deck claims differentiation through on-chip chemiluminescence and proprietary assay development † but discloses no patents filed, no patents granted, and no freedom-to-operate analysis. Abbott (i-STAT) and Biosite hold extensive immunoassay IP portfolios that could block or constrain Theranos's commercial path.
Mitigant.Diligence Q: full patent portfolio, filed, granted, and pending, plus freedom-to-operate opinion against Abbott and Biosite IP.
Covance, PPD, and Quintiles † are the existing infrastructure for Phase IV monitoring and hold long-term contracts with the same pharma sponsors Theranos targets. The deck does not address switching costs, incumbent contract terms, or why sponsors would replace a validated workflow with an uncleared device.
Mitigant.None identified.
The deck states the $30M Series B funds 'rapid scaling of production and manufacturing infrastructure' and sales force expansion † but provides no allocation percentages, no headcount plan, and no runway calculation. Investors cannot assess whether $30M is sufficient to reach the milestones the deck projects.
Mitigant.Require a 24-month operating budget with line-item allocation before closing.
Bull case · What has to go right
Technology must be independently validated as analytically equivalent to central lab standards; FDA clearance must be obtained on a timeline consistent with the 1.5-year revenue projection; at least one named pharma sponsor must convert from validation to a signed Phase IV contract.
Bear case · What could go wrong
The technology fails independent analytical validation; FDA clearance takes 3+ years or is denied; the 5 unnamed validation-phase customers decline to convert to paid contracts; the company burns the $30M on manufacturing infrastructure before generating any revenue.
Failure modes the partner would catalogue
The ABCS platform fails independent analytical validation, assay precision degrades outside controlled conditions or the 5-10µL sample volume is insufficient for the claimed dynamic range, and the entire commercial pipeline collapses before a single Phase IV contract is signed.
FDA requires a PMA pathway rather than 510(k) for a novel multiplex immunoassay used in regulated clinical trials, adding 2-4 years and $10M+ in clinical data requirements; the $30M raise is consumed before clearance is obtained and the company cannot raise a bridge.
The five unnamed validation-phase companies decline to convert to signed contracts after completing their evaluations, leaving Theranos with no contracted revenue, a depleted raise, and a pipeline of 15 deals that were never more than exploratory conversations.
Central lab CROs respond to Theranos's market entry by offering real-time data reporting through existing CLIA-certified infrastructure, removing the speed advantage without requiring pharma sponsors to validate a new, uncleared platform.
Diligence asks before taking the meeting.
Provide the full analytical validation dataset for the ABCS platform: peer-reviewed publications or independent lab reports confirming accuracy comparable to gold-standard central lab assays from 5-10µL blood samples, with precision data (CV%) across the claimed dynamic range.
CriticalThe entire investment thesis rests on this claim. Without independent validation, there is no basis for any revenue projection, margin assumption, or customer conversion expectation. This is the first question and the only one that matters until it is answered.
Disclose the FDA regulatory pathway for the ABCS platform: has a 510(k) or PMA submission been filed, and if so, when? If not filed, what is the regulatory strategy and timeline to clearance?
CriticalEvery dollar of projected revenue requires FDA clearance before a pharma sponsor can use the platform in a regulated Phase IV study. The 1.5-year revenue timeline † is structurally unreachable if clearance has not been filed. The answer determines whether the revenue projection is a plan or a wish.
Name the five companies in validation phase and provide deal documentation: signed agreements, LOIs, or term sheets, with revenue recognition timeline and patient enrollment schedule for each.
CriticalSix unnamed deals in validation phase is an unverifiable assertion. No reference checks, no contract verification, and no independent confirmation of deal status are possible without disclosure †. This is a complete due diligence block.
The deck never states these. Verdict left them blank rather than estimating them, so no figure in this memo was filled in from a guess.
Cost of goods sold and manufacturing cost structure not disclosed
Customer acquisition cost and sales cycle length not disclosed
Regulatory approval status and FDA pathway for diagnostic platform not disclosed
Intellectual property portfolio and patent status not disclosed
Clinical validation data and peer-reviewed publications not referenced
Reconciliation of $50M average revenue per trial with $7,500 per-patient fee and 2,000-10,000 patient range not provided
Use of funds allocation for $30M Series B not specified
Identity and deal status of 6 current customers (5 companies) not disclosed
Competitive landscape and named competitors not addressed
Identity and deal stage of 15 pipeline deals not disclosed
6 cited
† founder-stated, from the pitch deck · numbered sources are independently verified third parties
The research runs on the day the memo is written, so a source can be published after the deck.
About this memo
Verdict picked this company and ran the memo on its pitch deck. You are reading it in full, as it came out, with no edits after the fact. Because the company is one you can look up, the call is yours to judge rather than take on trust. Verdict is not affiliated with it, and a memo is a view formed from one deck at one moment.
Something look wrong? info@useverdict.io